VivoSeq
Other

Tyrosine Kinase Inhibitor

0

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Tyrosine Kinase Inhibitor is an early-stage landscape with 0 programs across 6 companies. The most active players are Pfizer, GSK, TG Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalT

TG Therapeutics, Inc.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalA

Astex Pharmaceuticals, Inc.

0 programs

PreclinicalB

Beijing InnoCare Pharma Tech Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed10 · 63%
Unknown status3 · 19%
Terminated2 · 13%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Completed·—·Phase 2·NCT02712112·51 enrolled
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Completed·Pfizer logoPfizer·N/A·NCT04647110·549 enrolled
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
Completed·RRadboud University Medical Center·N/A·NCT00979381·75 enrolled
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
Completed·GSK logoGSK·N/A·NCT01098500·3,800 enrolled
A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001696·15 enrolled
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT02733445·2,650 enrolled
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
Completed·AAEterna Zentaris·Phase 2·NCT00448721·24 enrolled
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Completed·QQurient Co., Ltd.·Phase 1·NCT04648254·51 enrolled
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
Completed·AAstex Pharmaceuticals, Inc.·Phase 1·NCT00894894·22 enrolled
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Completed·Pfizer logoPfizer·Phase 1/2·NCT00074854·87 enrolled
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Terminated·TTG Therapeutics, Inc.·Phase 1·NCT03671590·172 enrolled
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
Terminated·UUniversity of Bologna·Phase 2·NCT00511121·5 enrolled
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05039736
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Unknown status·GGuangdong Association of Clinical Trials·N/A·NCT04007835·120 enrolled
Malaysia Stop Tyrosine Kinase Inhibitor Trial
Unknown status·Ministry of Health, Malaysia·Phase 3·NCT02381379·118 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)